“Merck wouldn’t have done this if there wasn’t very good preliminary results from the clinical trials,” said Dr. John Leavitt, a senior biotech analyst with the research firm Nerac. “There must be some trial data that is being shared with Merck by NewLink on the progress of these clinical trials.”
Read the full Des Moines Register article here:
- 46New analyst brings extensive experience in engineering, energy and environmental systems Read the full release here.
- 42Forum has evolved for entrepreneurs to pitch ideas, concepts and challenges. Read the full release here.
- 39Our analyst John Leavitt, Ph.D., was recently featured in an article in USA Today. Take a look at it today! http://www.usatoday.com/story/money/business/2014/11/26/analyst-newlink-deal-boost-ebola-vaccine/19518217/